Switzerland approves Novavax’s Covid vaccine for 12-18 year olds
Swiss medical regulator Swissmedic has approved Novavax’s Nuvaxovid Covid-19 vaccine for children aged 12-18 years. The greenlight has also been given for its use as a booster for adults, ahead of an anticipated rise in infections this winter.
This content was published on
3 minutes
Swissmedic/swissinfo.ch/sb
Русский
ru
Швейцария одобрила вакцину от Novavax для детей 12-18 лет
“Nuvaxovid, the Covid-19 vaccine from Novavax, is now approved for young people aged 12 and over with immediate effect,” Swissmedic said in a statementExternal link on Friday.
The approval is for the vaccine’s two-dose series of 50ml per dose, Swissmedic said. These are administered at an interval of three weeks, it added.
The Swiss medical regulator had approved the protein-based Nuvaxovid vaccine for adults in April, making it the fourth Covid-19 vaccine authorised in the country. The others are mRNA vaccines from Pfizer/BioNTech and Moderna and a viral vector vaccine from Johnson & Johnson.
More
More
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
According to Swissmedic, the Nuvaxovid vaccine contains a non-infectious component from the surface of the SaRS-CoV-2 virus, which triggers a protective immune response when the body’s immune cells come into contact with it. The vaccine contains an adjuvant to strengthen the immune response. It can be stored in a refrigerator for up to nine months.
It made its debut well after the first set of Covid-19 shots – including those from Moderna, Pfizer/BioNTech, AstraZeneca and Johnson & Johnson – were approved in different parts of the world.
The hope was Nuvaxovid would incentivise people who were sceptical of some shots based on the newer mRNA technology to get vaccinated, given Nuvaxovid relies on technology that has been used for decades to combat diseases including hepatitis B and influenza. However, demand has been tepid.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
So far, 69% of the Swiss population have been fully vaccinated against the virus.
Earlier this week Swissmedic gave temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
In view of the increase in cases in early summer 2022, the Swiss authorities recommended on July 5 that over-80s and vulnerable people should get a Covid booster shot. A similar recommendation for the rest of the adult population is expected in autumn.
Following a drop in cases, the number of new infections rose again between May and early July due to two new Omicron subvariants, BA.4 and BA.5. This latest wave has begun to subside. The health office reported 15,302 new Covid cases on August 30 for the previous seven-day period, down 10.1% on the previous week. There were 168 new hospital admissions and 17 reported deaths.
More
More
Switzerland approves vaccine that targets two Covid variants
This content was published on
Swissmedic awards temporary approval for new Covid-19 vaccine from Moderna, adapted to give protection against two different strains.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
Switzerland approves vaccine that targets two Covid variants
This content was published on
Swissmedic awards temporary approval for new Covid-19 vaccine from Moderna, adapted to give protection against two different strains.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Health experts recommend booster jab against Covid
This content was published on
The Swiss health authorities have called on people over the age of 80 to update their vaccination against the Covid-19 virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.